間葉系幹細胞の世界市場

◆英語タイトル:Global Mesenchymal Stem Cells Industry
◆商品コード:GIA61109
◆発行会社(調査会社):Global Industry Analysts
◆発行日:2016年9月
◆ページ数:184
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥559,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Industry Analysts社の日本における正規販売代理店です。Global Industry Analysts社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、間葉系幹細胞の世界市場について調査・分析し、間葉系幹細胞の世界市場規模、市場動向、市場予測、関連企業情報などをお届けいたします。
【レポートの概要】

This report analyzes the worldwide markets for Mesenchymal Stem Cells in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 47 companies including many key and niche players such as –
Aastrom Biosciences, Inc.
Cell Applications, Inc.
Celprogen, Inc.
Cyagen Biosciences Inc.
MilliporeSigma

【レポートの目次】

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers………….. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW………….. II-1 Mesenchymal Stem Cells Market on a Rapid Growth Path II-1 Current and Future Analysis…………..II-2 The Present and Future of MSC Therapies II-2 Select MSC-based Therapeutics II-3 Mesenchymal Stem Cell Research II-3 Table 1: Mesenchymal Stem Cells-based (MSCs) Clinical Trials by Region (2015) (includes corresponding Graph/Chart) II-4 Top 10 Countries Conducting Mesenchymal Stem Cells-based ( MSCs) Clinical Trials 2015…………..II-5 Table 2: China Leads the MSC-based Clinical Trials: 2010-2015 (includes corresponding Graph/Chart) II-5

Table 3: China’s MSC-based Clinical Trials by Phase: 2015 (includes corresponding Graph/Chart) II-6

Table 4: China’s MSC-based Clinical Trials by Source: 2015 (includes corresponding Graph/Chart) II-6

Table 5: China’s MSC-based Clinical Trials by Indication: 2015 (includes corresponding Graph/Chart) II-7 MSCs are Being Explored for Several New Treatment Possibilities II-7 Widespread Commercialization of ‘Off-the-Shelf’ MSCs to Become a Reality………….. II-8 Software Companies Endeavour to Cash in on the Boom II-9

2. MARKET DRIVERS, TRENDS & ISSUES II-10 Development of Regenerative Medicine Accelerates Demand for MSCs II-10 Table 6: Global Regenerative Medicines Market by Category (2015): Percentage Breakdown for Biopharmaceuticals, Cell and Tissue-Based Therapies, and Regenerative Devices & Compounds (includes corresponding Graph/Chart) II-10 Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies………….. II-11 Global Aging Population Statistics – Opportunity Indicators II-12 Table 7: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart)………….. II-12

Table 8: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart) II-13

Table 9: Life Expectancy at Age 60 and 80 Years – (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)…………..II-14

Table 10: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart) II-15 Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells…………..II-16 Key Disease Statistics – Opportunity Indicators II-16 Table 11: Worldwide Incidence of Cancer (2012, 2020 & 2030): Number of New Cases Diagnosed (includes corresponding Graph/Chart)………….. II-16

Table 12: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)………….. II-17

Table 13: Fatalities by Heart Conditions – Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)………….. II-17

Table 14: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart) II-18 Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market………….. II-18 Table 15: Global Orthopedic Market by Segment (2015): Percentage Breakdown of Value Sales for Extremities, Hips, Knees, Orthobiologics, Spine, Trauma and Others (includes corresponding Graph/Chart)…………..II-19 Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research II-19 Adult Stem Cells and Embryonic Stem Cells – A Comparison II-20 MSCs versus Embryonic or Induced Pluripotent Stem Cells II-20 MSC Therapies – Immune to Ethical Issues Applicable to Embryonic Stem Cells…………..II-20 MSCs – A Potential Vehicle for ‘Targeted Drug Delivery’ II-21 Stem Cell Based Bone Grafts: Promising Growth Ahead II-22 Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements…………..II-23 Major Challenges Confronting Mesenchymal Stem Cell Market II-24 Allogeneic MSCs – Offering Promise in Immunosuppressive and Tissue Repair Therapy…………..II-24 Administration Route Determines the Effectiveness of MSCs II-25

3. REVIEW OF SELECT MAJOR STEM CELL VARIANTS II-27 Adult Stem Cells………….. II-27 A Low Risk Investment…………..II-27 Adult Stem Cells Garner More Investments for Research II-27 Low Versatility – A Major Limiting Factor for Adult Stem Cells II-27 Hematopoietic Stem Cells – Enjoying Enduring Success II-27 Restraining Factors…………..II-28 Induced Pluripotent Stem Cells – An Alternative to ESCs II-28 A Peek into the Discovery of iPS II-28 Drug Development – A Major Application for iPS II-29 Use of iPS for Regenerative Medicine II-29 Establishing iPS Cell Banks…………..II-29 Intractable and Congenital Disease Treatments II-29 Embryonic Stem Cells to Transfigure Medicine II-30 Ethical Issues and Technical Hurdles Bog Down hESC Research II-30 Lack of Safety and Efficacy Data – A Key Concern II-30

4. MESENCHYMAL STEM CELL RESEARCH BY APPLICATION II-31 Mesenchymal Stem Cells in Orthopedics II-31 MSC based Models for Orthopedic Repair II-31 Delivery of MSCs to Regions Requiring Therapy II-31 MSCs in the Treatment of Osteoarthritis II-32 MSCs in the Treatment of Rheumatoid Arthritis II-32 MSCs in Cancer Treatment…………..II-32 MSCs in Hepatology…………..II-33 MSCs in Neurology………….. II-33 MSCs in Cardiology…………..II-34 MSCs in Radiotherapy…………..II-35 MSCs in the Treatment of Diabetes II-35 MSCs in the Treatment of Autoimmune Diseases II-36 MSCs in Treatment of Premature Ovarian Failure II-36 MSCs for Gene Therapy…………..II-37 MSC Therapy in the Treatment of Lung Diseases II-37 MSCs for Treating Liver Disease…………..II-39 MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US (2016)…………..II-39 MSCs in Colon Repair…………..II-40 MSCs in Kidney Repair…………..II-41

5. PRODUCT OVERVIEW………….. II-42 Mesenchymal Stem Cells (MSCs) – An Introduction II-42 History………….. II-42 What Are Allogeneic Mesenchymal Stem Cells? II-43 Some Major Sources of Mesenchymal Stem Cells II-43 Bone Marrow………….. II-43 Wharton’s Jelly and Umbilical Cord Blood II-43 Adipose Tissue………….. II-43 Trophoblastic Tissues…………..II-44 Amniotic Fluid………….. II-44 Developing Tooth Bud of Mandibular Third Molar II-44 Mechanism of Mesenchymal Stem Cell Therapy II-44 Important Features of Mesenchymal Stem Cells II-45 Morphology………….. II-45 Identification/Detection…………..II-45 Differentiation Capacity…………..II-46 Immuno-modulatory Effects…………..II-46 Culturing………….. II-46 Clinical Use………….. II-47 Production of Clinical-Grade MSCs II-47 Drawbacks of MSCs………….. II-47

6. RECENT INDUSTRY ACTIVITY…………..II-48 JCR Pharmaceuticals Develops TEMCELL HS II-48 Stemedica Receives FDA Approval for Phase Iia Clinical Study for Traumatic Brain Injury…………..II-48 PuRec Announces Plans to Produce MSCs/RECs II-48 Stemedica Enrolls into Phase I/IIa Clinical Study for Ischemic Stroke………….. II-48 JCR Pharmaceuticals Receives Pricing Notification II-48 JCR Pharmaceuticals Awaits Approval for JR-031 II-49 Stemedica Receives FDA’s Approval for Phase Iia Clinical Study II-49 Mesoblast Announces Plans to Introduce Stem Cell Therapy Product II-49 Stemedica Receives Patent…………..II-49 Stem Cell and Cancer Institute Receives IND approval II-49 Thermo Fisher Scientific Takes Over Life Technologies II-49

7. FOCUS ON SELECT PLAYERS…………..II-50 Cell Applications, Inc. (US)…………..II-50 Celprogen, Inc. (US)…………..II-50 Cyagen Biosciences, Inc. (US)…………..II-50 MilliporeSigma (US)………….. II-51 Genlantis, Inc. (US)…………..II-51 Thermo Fischer Scientific, Inc. (US) II-52 Lonza Group (Switzerland)…………..II-52 Mesoblast Limited (Australia)…………..II-52 Neuromics (US)………….. II-53 Orthofix International N.V. (Curacao) II-54 PromoCell GmbH (Germany)…………..II-54 R&D Systems, Inc. (US)…………..II-54 ScienCell Research Laboratories (US) II-55 Stemcell Technologies Inc (Canada) II-55 Stemedica Cell Technologies, Inc. (US) II-56 Trevigen, Inc. (US)………….. II-56 Vericel Corporation (US)…………..II-57 Vitro Biopharma (US)…………..II-57

8. GLOBAL MARKET PERSPECTIVE…………..II-58 Table 16: World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)…………..II-58

Table 17: World Historic Review for Mesenchymal Stem Cells by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 Through 2014 (includes corresponding Graph/Chart) II-59

Table 18: World 14-Year Perspective for Mesenchymal Stem Cells by Geographic Region – Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-60

III. MARKET

1. THE UNITED STATES………….. III-1 A.Market Analysis………….. III-1 Rapidly Ageing Population: A Major Driving Demand for MSC based Therapies…………..III-1 Table 19: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart) III-2 Increasing Incidence of Chronic Diseases Drives Focus onto MSCs III-2 Table 20: CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)………….. III-3

Table 21: New Cancer Cases in Males in US by Body Site (2014) (includes corresponding Graph/Chart) III-3

Table 22: New Cancer Cases in Females in US by Body Site (2014) (includes corresponding Graph/Chart) III-4 Arthritis………….. III-4 Table 23: % of Population Diagnosed with Arthritis by Age Group (includes corresponding Graph/Chart) III-4 Prochymal Obtains Fast Track Designation from FDA III-5 MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US…………..III-5 Rising Governmental Investments in Stem Cell Therapies – A Growth Booster………….. III-6 FDA Issues Warning Against Illegal Stem Cell Therapies III-7 US Regulates Stem Cells as Drugs III-7 Federal Law on Stem Cells in the US III-7 NIH at the Forefront of Research Funding III-8 NIH Guidelines on Stem Cell Research Funding III-8 Bans and Restrictions on Stem Cell Research III-8 American Type Culture Collection Inc (ATCC) – A Major Non- Profit Organization…………..III-8 Strategic Corporate Developments III-9 Select Key Players…………..III-10 B.Market Analytics…………..III-17 Table 24: The US Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)…………..III-17

Table 25: The US Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-18

2. CANADA………….. III-19 A.Market Analysis………….. III-19 Current and Future Analysis…………..III-19 Prochymal – Canada’s First MSC-based Therapy III-19 Stemcell Technologies Inc – A Key Player III-19 B.Market Analytics…………..III-20 Table 26: Canadian Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)…………..III-20

Table 27: Canadian Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)………….. III-21

3. JAPAN………….. III-22 A.Market Analysis………….. III-22 Current and Future Analysis…………..III-22 Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Mesenchymal Stem Cells………….. III-22 Table 28: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart) III-22

Table 29: Cancer Related Deaths by Age Group in Japan (2013) (includes corresponding Graph/Chart) III-23 New Regulation for Accelerated Stem Cell Approval and Its Impact on Stem Cells Product Market III-23 Strategic Corporate Development III-24 B.Market Analytics…………..III-24 Table 30: Japanese Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)…………..III-24

Table 31: Japanese Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)………….. III-25

4. EUROPE………….. III-26 A.Market Analysis………….. III-26 Current and Future Analysis…………..III-26 Ageing Population to Drive Demand for MSC based Therapies III-26 Table 32: European Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) III-27

Table 33: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)…………..III-28 Cancer in Europe: Key Statistics III-29 Table 34: Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart) III-29 Legislations on Stem Cell Research and Therapy in the EU III-29 Unproven Stem Cell Therapies Receive Government Backing in the EU?………….. III-30 Scientists and Government Tussle over Safety of Stamina Foundation’s MSC Therapy in Italy III-30 Stem Cell Clinics Shut Down in Germany due to Malpractices III-30 Key Players………….. III-31 B.Market Analytics…………..III-32 Table 35: European Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)…………..III-32

Table 36: European Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)………….. III-33

5. ASIA-PACIFIC………….. III-34 A.Market Analysis………….. III-34 Current and Future Analysis…………..III-34 Overview of Select Countries III-34 Australia………….. III-34 Stem Cell Tourism – A Popular Trend in Australia III-34 South Korea………….. III-34 South Korea Pacing towards Regaining Lost Glory in Stem Cell Research…………..III-34 South Korea Upbeat on Stem Cell Therapy Market Potential III-35 India………….. III-35 An Outline of the Stem Cell Research Structure in India III-35 Table 37: Indian Adult Stem Cell Research (2012): Percentage Share Breakdown by Type (includes corresponding Graph/Chart)…………..III-36 A Regulatory Picture of the Indian Stem Cell Research and Therapy………….. III-36 Adult Stem Cells – A Highly Money-Spinning Market III-37 Indians ‘Bank’ on Dental Stem Cells III-37 New Zealand………….. III-38 Stem Cell Research Scenario in New Zealand III-38 Product Launches…………..III-38 Key Players………….. III-39 B.Market Analytics…………..III-42 Table 38: Asia-Pacific Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-42

Table 39: Asia-Pacific Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)………….. III-43

6. REST OF WORLD………….. III-44 A.Market Analysis………….. III-44 Current and Future Analysis…………..III-44 Stem Cell Research in Full Swing in Israel III-44 Key Players………….. III-45 B.Market Analytics…………..III-47 Table 40: Rest of World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-47

Table 41: Rest of World Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)………….. III-48

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 47

The United States (25) Canada (1) Japan (2) Europe (6) – Germany (2) – The United Kingdom (1) – Rest of Europe (3) Asia-Pacific (Excluding Japan) (9) Latin America (1) Middle East (3)



★調査レポート[間葉系幹細胞の世界市場] (コード:GIA61109)販売に関する免責事項を必ずご確認ください。
★調査レポート[間葉系幹細胞の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆